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Project Goals
• Develop a plan for the screening of the 
general public for Alzheimer’s Disease 
Background
Cause:
• As the body ages, β-amyloid plaques and 
neurofibrillary tangles may build up in the brain
• These block communication between cells 
Diagnosis:
• Most widely used form of definitive diagnosis 
is an autopsy
• Patients can be diagnosed with “Alzheimer’s 
Type” pathology based on symptoms such as 
memory loss and other cognitive tests
• A newly developed, accurate test for AD is a 
PET scan, administered with radioactive tracers
• Effective diagnosis of the disease can be 
achieved through an efficient, widespread 
system of screening
PET Scans
• Positron emission tomography shows how 
well cells are working based on the amount of 
sugar or oxygen the cell consumes
• A radioactive tracer can be given to the 
patient so that the PET scan will show the 
targeted cell
http://www.researchmalignantmesothelioma.com/pet-scan.html
http://www.alz.org/index.asphttp://library.med.utah.edu/WebPath/CNSHTM
L/CNS088.html
http://library.med.utah.edu/WebPath/CNSH
TML/CNS090.html
PET Scan Screening For Alzheimer’s
• Used to measure the levels of β-amyloid plaques as well as neurofibrillary tangles
• A radioactive tracer, 18F-FDDNP, binds to the plaques and tangles 
• An administered PET scan shows where the tracer is greater in concentration
• FDG PET scans use the tracer 18 FDG to show brain metabolic activity 
• Administration of these two tests is enough to diagnose Alzheimer’s Disease 
Diagnostic Screening System
• “At-risk” patients will be given a standard cognitive assessment called a Mental Status 
Examination (MSE) as a part of their yearly physical examination
• If the patient’s score declines significantly over the course of one or more years, the 
physician must refer them to a hospital for plaque screening and a FDG PET scan
• If the results show that the patient has signs of AD, treatment will be carried out
Mental Status Examination (MSE)
• Evaluates:
• Affect and mood
• Attitude
• Appearance
• Behavior
• Cognition
• Insight judgment
• Speech and language
• Thought content
• Thought processes
(2004) Nature 430: 631-639.Helmuth L (2002) Science 297: 752-753.
“At Risk Patients”
• Patients already diagnosed with “Alzheimer’s 
type” pathology
• Those with a family history of Alzheimer’s over 
the age of 40
Funding and Cost
• The average cost of a basic PET scan is 
between $3,000 and $6,000
• Most insurance companies will cover the cost if it 
has been clinically indicated
• Changes in Medicare would result in the 
reimbursement of these costs to patients of a 
certain age
Ethics
• Does the treatment really improve their quality 
of life?
• Will the screening 
create more paranoia 
and harm?
• Will treatment create 
false hope? http://www.smh.com.au/news/health/new-hope-in-fight-against-alzheimers/2008/03/15/1205472166682.html
Conclusion
• An organized, widespread screening 
system for Alzheimer’s Disease will 
result in the earlier treatment of 
patients and possibly a decrease in 
the mortality rate due to this  
degenerative condition.
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• The frontal lobe deals with 
thinking and planning
• Temporal lobe is 
responsible for memory and 
learning
• These are the two areas 
affected most by Alzheimer’s
http://www.brainhealthandpuzzles.com/diagram_of_brain.html
Cause 2000 2006 Percentage Change
 Heart disease  710,760 629,191  -11.5  
 Breast cancer 41,200 40,970  -0.6  
 Prostate cancer  31,900 27,350  -14.3  
 Stroke  167,661 137,265  -18.1  
 Alzheimer’s disease 49,558 72,914  +47.1  
Percentage Changes in Selected Causes of Death, 2000 and 2006
